About ADAPT Pharma
ADAPT Pharma is a company based in Dublin (Ireland) founded in 2014 by Seamus Mulligan and David Brabazon was acquired by Emergent BioSolutions in August 2018. ADAPT Pharma operates in a competitive market with competitors including Indivior, Biotie, Ethypharm, Braeburn and Opiant Pharmaceuticals, among others.
- Headquarter Dublin, Ireland
- Founders Seamus Mulligan, David Brabazon
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website adaptpharma.com
- Social LinkedIn X
- Acquired by Emergent BioSolutions (Aug 2018)
- Investors
- Acquired byEmergent BioSolutions
(Aug 2018)
Investors in ADAPT Pharma
ADAPT Pharma has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Emergent BioSolutions.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Vaccines for viral infections are developed by the company. | 1998 | emergentbiosolutions.com | Gaithersburg, United States |
Investor details for ADAPT Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of ADAPT Pharma
2 people are tracked at ADAPT Pharma (2 in leadership).
| Name | Role | Group |
|---|---|---|
Seamus Mulligan | Co-Founder & Co- CEO | Leadership |
David Brabazon | Co-Founder & CFO | Leadership |
Complete people profiles for ADAPT Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of ADAPT Pharma
2 dated milestones of ADAPT Pharma across 4 years, from founding to its latest funding, stage changes and deals.
- Founded ADAPT Pharma is founded.
- Exit Acquired by Emergent BioSolutions.
Competitors of ADAPT Pharma
ADAPT Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Indivior, Biotie, Ethypharm, Braeburn and Opiant Pharmaceuticals, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| indivior.com | 2014 | Richmond Hill, United States | – | 1,051 | Therapeutics for opioid addiction treatment are developed and commercialized. | |
| biotie.com | 1998 | Turku, Finland | $149.81M | 27 | Drugs for neurodegenerative and psychiatric disorders are developed by Biotie. | |
| ethypharm.com | 1977 | Saint Cloud, France | $248.09M | – | Therapies for pain and addiction treatment are developed. | |
| braeburnrx.com | 2012 | Philadelphia, United States | $110M | – | Long-acting therapies for opioid addiction and chronic pain are developed. | |
| opiant.com | 2005 | Santa Monica, United States | – | 31 | Therapeutics for addictive and eating disorders are developed. | |
| amygns.com | 2015 | San Francisco, United States | $7.05M | – | Therapies for substance use disorders are developed by Amygdala Neurosciences. | |
| 4p-pharma.com | 2014 | Lille, France | $18.49M | – | French Biotech startup that develops to clinical trial stage the molecules it has in-licensed | |
| cessationtherapeutics.com | 2017 | San Jose, United States | $6.76M | – | Developer of immunotherapy based vaccines to manage addictions | |
| titanpharm.com | 1992 | San Francisco, United States | – | 11 | A specialty pharmaceutical company developing proprietary therapeutics for select chronic diseases | |
| aelisfarma.com | 2013 | Bordeaux, France | $14.04M | – | Developer of small molecule drugs targeting CB1 receptor for CNS diseases |
Detailed competitors of ADAPT Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Adapt Pharma
Complete news archive for ADAPT Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to ADAPT Pharma
10 companies that operate in the same segment as ADAPT Pharma (Neurology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided. | 1999 | Tirat Carmel, Haifa District, Israel | USD 574.2 M | – | – | |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers | 2019 | San Francisco, California, United States | USD 144.72 M | – | 76 | |
Small molecule drugs for rare diseases are developed. | 1998 | South Plainfield, New Jersey, United States | USD 248.1 M | USD 1.73 B | 939 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about ADAPT Pharma
ADAPT Pharma was founded in 2014.
ADAPT Pharma is headquartered in Dublin, Ireland.
Seamus Mulligan is the current CEO of ADAPT Pharma. They have also founded this company.
ADAPT Pharma was founded in 2014 in Dublin, Ireland, within the pharmaceutical sector. Emergency therapeutic conditions are addressed through the development of opioid antagonist therapies. The lead candidate, NARCAN (naloxone HCl), has been reformulated as a nasal spray for treating opioid overdoses. Fast Track Designation and priority review have been granted to this product by regulatory authorities.
ADAPT Pharma's top competitors include Indivior, Ethypharm and Amygdala Neurosciences.
ADAPT Pharma has 1 investor. Key investors include Emergent BioSolutions.
Yes. ADAPT Pharma was acquired by Emergent BioSolutions in August 2018.